Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
| Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 65.32M | $ 67.64M | $ 79.20M | $ 86.16M | $ 97.07M |
| Gross Profit | $ 60.74M | $ 67.64M | $ 79.20M | $ 86.16M | $ 97.07M |
| Operating Income | $ -85.35M | $ -121.69M | $ -137.21M | $ -123.84M | $ -109.57M |
| EBITDA | $ -70.78M | $ -104.51M | $ -123.48M | $ -119.22M | $ -104.25M |
| Net Income | $ -81.89M | $ -116.05M | $ -133.82M | $ -121.75M | $ -79.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 188.86M | $ 248.19M | $ 369.91M | $ 249.23M | $ 244.00M |
| Total Assets | $ 280.73M | $ 376.65M | $ 462.27M | $ 380.59M | $ 440.86M |
| Total Debt | $ 201.06M | $ 226.06M | $ 222.44M | $ 26.69M | $ 6.83M |
| Net Debt | $ 168.76M | $ 188.82M | $ 137.05M | $ -17.31M | $ -50.37M |
| Total Liabilities | $ 216.01M | $ 247.84M | $ 245.54M | $ 59.26M | $ 41.43M |
| Stockholders' Equity | $ 64.72M | $ 128.81M | $ 216.74M | $ 321.33M | $ 399.43M |
| Cash Flow | |||||
| Free Cash Flow | $ -32.17M | $ -96.71M | $ -112.21M | $ -86.91M | $ -70.75M |
| Operating Cash Flow | $ -19.27M | $ -78.76M | $ -103.15M | $ -84.78M | $ -70.00M |
| Investing Cash Flow | $ 40.35M | $ 58.23M | $ -53.58M | $ 54.90M | $ 36.99M |
| Financing Cash Flow | $ -26.62M | $ -27.63M | $ 198.13M | $ 20.03M | $ 3.08M |